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Abstract
Breast cancer (BC) is the most common cancer in women and second only to lung
cancer  in  terms  of  mortality.  Among  the  three  different  BC  subtypes,  the
oestrogen receptor positive represents nearly 70% of all cases and it is usually
treated with anti-oestrogen drugs. However, the majority of hormone receptor
positive metastatic BC patients develop resistance to anti-oestrogen treatments.
The  need  for  more  down-stream  therapies  brought  to  the  development  of
therapeutic strategies inhibiting the phosphatidylinositol 3-kinase-mammalian
target of rapamycin (mTOR) pathway. Inhibitors of the mTOR have been tested
in different clinical trials; everolimus has been Food and Drug Administration
approved for the treatment of oestrogen receptor positive/human epidermal
growth factor receptor 2 negative BC patients in combination with exemestane in
patients who have progressed to anastrozole or letrozole after the encouraging
results  coming  from  BOLERO-2  trial.  Similar  results  were  obtained  by  the
TAMRAD investigatory study testing tamoxifen in combination with everolimus
in advanced BC. This editorial focuses on the results from BOLERO-2, BOLERO 4
and BOLERO-6, which tested the clinical importance of mTOR inhibition. We
comment also on the role of phosphatidylinositol 3-kinase-mTOR inhibition as
reported in the BELLE-2 and BELLE-3 trials and the future directions for the
inhibition of this tumour metabolic axis.
Key words:  Hormone receptor  positive/Her2-negative breast  cancer;  PI3K; mTOR;
TORC1/2; Akt; Everolimus
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: The phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-
mTOR) pathway sustains cancer progression and drug resistance. The first Food and
Drug Administration approved molecule against this pathway was everolimus, an mTOR
inhibitor,  to  be  used  in  combination  with  exemestane  in  hormone  receptor
positive/human epidermal growth factor receptor 2 negative breast cancers progressing
to non-steroidal aromatase inhibitors. Drugs targeting other effectors such as PI3K,
PI3Kα, Akt and mTORC1/2 have gained clinical interest.  Nevertheless, everolimus
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remains the best option due to the relevant toxicity of the other drugs targeting the PI3K-
mTOR pathway. Future directions point towards the development of biomarkers that
would identify those patients who would benefit from the PI3K-mTOR inhibitors for
improving overall survival.
Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Current status of PI3K-
mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World J
Clin Oncol 2018; 9(8): 172-179
URL: https://www.wjgnet.com/2218-4333/full/v9/i8/172.htm
DOI: https://dx.doi.org/10.5306/wjco.v9.i8.172
INTRODUCTION
With the introduction of molecular technologies, breast cancer (BC) has been divided
into four main subtypes:  luminal  A,  luminal  B,  human epidermal  growth factor
receptor  2  (HER2),  or  triple  negative.  The luminal  variants,  due to the hormone
receptor positive (HR+) expression, have a generally favourable prognosis in the non-
metastatic setting. Some of the most commonly used drugs for the treatment of HR+
disease have been anti-oestrogen therapies, e.g. tamoxifen and aromatase inhibitors
(AI) - such as anastrozole or letrozole or exemestane. In BC survivors, metastatic
breast cancer (MBC) is a treatable but still incurable disease. The majority of HR+
MBCs develop resistance to anti-oestrogen treatments[1,2]. Cancer driver mutations
and/or  constitutive  activation  in  the  key  signalling  pathway  genes  of
phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) cascade
are  capable  of  overriding  anti-oestrogen  treatments  in  BC  cells[3].  In  particular,
PIK3CA is mutated in 20%-40% of BC[4,5], representing therefore an interesting target
for therapies. For these reasons, inhibitors of the PI3K-mTOR pathway was pursued
in  clinical  development  until  one  of  them,  an  mTOR  inhibitor-a  derivative  of
rapamycin  -  named everolimus,  reached  Food and Drug  Administration  (FDA)
approval for the treatment of the disease in 2012, in combination with exemestane, for
second  line  treatment  of  HR+/HER2-  BCs  that  have  previously  regressed  to
anastrozole or letrozole treatment.
This commentary is focused on the outcomes coming from the most important
clinical  trials,  testing  everolimus  in  combination  with  other  drugs:  TAMRAD
(Tamoxifen  Plus  Everolimus),  BOLERO-2  (OraL  EveROlimus-2),  BOLERO-4,
BOLERO-6,  BELLE-2  and  BELLE-3.  Future  directions  and  perspectives  testing
therapeutical combinations targeting different effectors are also discussed.
PI3K-mTOR PATHWAY
PI3K-mTOR  signaling  events  play  an  important  role  in  the  modulation  of  cell
survival, proliferation, motility and apoptosis: activation of PI3K phosphorylates Akt,
shifting  thereby  the  protein  in  the  activated  form  that  localizes  in  the  plasma
membrane. Subsequently a cascade of downstream events are activated, including the
inhibition  of  p27  and  the  increase  of  the  transcription  factor  CREB  levels  and,
consequently, of the cell cycle promoter cyclin A, leading to mTOR activation that
promotes the expression of genes related to cell proliferation. The aberrant activation
of the PI3K-mTOR pathway sustains cancer cell survival and proliferation and also
contributes to anti-oestrogen treatment resistance.
PIK3CA mutations constitutively activate the PI3K signal transduction pathway,
which ultimately leads to the phosphorylation of PIP2 into PIP3, thus activating the
phosphatidylinositol signalling bringing to higher cell survival and to inhibition of
apoptosis. Predominantly mutations of PI3KCA occur around hotspots E542/5 (exon
9)  and  H1047  (exon  20)  at  the  catalytic  subunit[6-9].  Additionally,  AKT  or  PTEN
mutations overrides anti-oestrogen therapies[4,10]. Eventually, PIP3 phosphorylates Akt
(pAkt is the active form), which then activates the mTOR.
Of note,  PI3K activation has been shown to cause a decrease in ER levels  and
therefore a lesser degree of response to anti-oestrogen therapies[11]. Targeting PI3K
could be  capable  of  restoring  ER sensitivity[12].  Therefore,  PI3K-mTOR pathway
inhibition plus endocrine therapies represent an interesting strategy to pursue. There
is a link between ER and mTORC1: mTORC1 can phosphorylate ER at S167 through
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p70S6K  or  it  can  also  phosphorylate  ER  at  S104/S106,  thus  resulting  in  ER
activation[13]. Of note, recently, Sonnenblick et al[14] discovered a gene signature related
to  the  phosphorylation  of  Akt  (pAkt)  and  mTOR  (p-mTOR)  in  early  ER+  BC.
Analyzing gene expression and proteomic data collected from over 7000 early BC,
they found pAkt correlated to luminal A and a good prognosis, whereas p-mTOR was
found in worse prognosis luminal B cases. Interestingly, the signatures of pAkt and p-
mTOR correlated to PI3KCA mutations positively and negatively, respectively. The
authors underlined the different role at the molecular level of pAkt and p-mTOR
effectors in early luminal BC, a matter that further contributes to the heterogeneity of
the disease[14].
CLINICAL TRIALS
The discovery of everolimus led to the hypothesis of synergism in co-targeting two
different pathways in HR+/HER2- advanced BC patients: the mTOR and the HRs
pathways. Such hypothesis has been tested in several clinical trials.
The  TAMRAD  trial  was  a  phase  2,  randomized  clinical  trial  that  tested  the
combination of everolimus with tamoxifen in postmenopausal women with MBC and
resistance to AI.  Besides proving to be a safe approach, it  demonstrated that the
combination of these treatments was capable of increasing the clinical benefit rate
(CBR) from 42% with tamoxifen to 61% with the combination. The time to progression
increased from 4.5 mo in patients receiving only tamoxifen to 8.6 mo in patients
receiving both tamoxifen and everolimus. The death risk was reduced by 55% after
treating patients with tamoxifen plus everolimus in comparison to tamoxifen alone[15].
Interestingly, the combination was efficient in patients who responded to AIs but
subsequently became resistant to AIs. Contrarily, the combination was not effective in
de novo treated MBC HR+[16].
The  BOLERO-2 trial  was  a  phase  3,  randomized,  double-blinded,  multicentre
clinical trial that recruited 724 HR+ MBC patients. This trial evaluated everolimus
with the steroideal AI as exemestane compared to exemestane and placebo. Patients
who were enrolled in this clinical trial had previously received AI anastrozole or
letrozole. This clinical trial showed an improved progression free survival (PFS) of 11
mo  in  the  exemestane  +  everolimus  arm  compared  to  the  4.1  mo  placebo  +
exemestane ones [P < 0.0001; hazard ratio = 0.38; 95% confidence interval (CI): 0.31-
0.48][17]. This shows that the combination of everolimus with exemestane doubled up
the PFS time versus placebo plus exemestane alone; these results led to the FDA
approval of everolimus with exemestane in the treatment of HR+ MBC patients who
did not respond to letrozole nor anastrozole treatments.
Recent studies further tested everolimus in combination with other therapies as
first  line  in  HR+  BC  patients.  The  BOLERO-4  (NCT01698918)  and  BOLERO-6
(NCT01783444) tested everolimus with different combinations of drugs. BOLERO-4
was a single arm, open labeled phase 2 study evaluating in 202 ER+, HER2- advanced
BC patients the PFS of first line everolimus + letrozole and in a quarter of them whose
disease progressed, everolimus + exemestane as second line. This study demonstrated
the efficacy of everolimus + letrozole with a median PFS of 22 mo, whereas the second
line everolimus + exemestane, which was used in some of the progressed patients,
gave limited results  with a  median PFS of  only 3.7  mo[18].  The BOLERO-6 was a
randomized open-labeled study,  comparing  second line  therapies  everolimus  +
exemestane against everolimus or capecitabine alone in 309 AI-resistant ER+, HER2-
MBC patients. Consistent with the BOLERO-2 study, robust evidence of superiority in
median PFS was registered for everolimus + exemestane versus everolimus alone but
surprisingly not versus capecitabine alone. However, the authors pointed out that
there were some limits to the study, such as censored data and baseline imbalance in
Kaplan Meyer curves, that could have inferred on the evaluation of the capecitabine
arm[19]. Thus, the combination of everolimus + exemestane was confirmed to benefit
these patients, whereas the superiority/equivalence/inferiority of capecitabine needs
further clinical evaluation.
Inhibition of PI3K has been also investigated as an alternative strategy in targeted
therapies of the mTOR pathway. As an example, buparlisib (BKM120), which is a
PI3K  inhibitor,  has  been  tested  in  combination  with  fulvestrant  in  patients
progressing  AIs  (BELLE-2,  NCT01610284)  and  in  patients  progressing  mTOR
inhibition (BELLE-3, NCT01633060).
Buparlisib  has  been tested in  1147  patients  as  second line  in  the  randomized,
double-blinded BELLE-2 clinical trial, alone or in combination with fulvestrant. It was
clear  that  the  combination  with  the  PI3K  inhibitor  had  slightly  increased  PFS
compared to fulvestrant alone, with the exception of PI3KCA mutated patients who
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improved the PFS of about 4 mo. Of note, the serious toxicity of buparsilib limited the
efficacy of the targeted therapy[20]. BELLE-3 was a randomized double-blinded phase 2
trial  enrolling  432  patients  who progressed  AIs  to  evaluate  PFS  in  buparlisib  +
fulvestrant arm compared to fulvestrant + placebo. The combination with buparlisib
improved the PFS of only 2 mo while showing a high toxicity profile that hampered
the clinical benefit[21]. Finally, an exploratory strategy is aiming for the simultaneous
inhibition of PI3K and mTOR by alpelisib (BYL719) and everolimus, respectively. The
safety  of  the  combination  of  alpelisib  and  everolimus  alone  or  everolimus  +
exemestane has been tested in a Phase 1 trial in various solid tumours, including BC
(NCT02077933).
Worth of note is the combination of letrozole and alpelisib, a selective oral inhibitor
of the class I PI3K catalytic subunit p110α, which has shown synergistic antitumour
activity  with  endocrine  therapy  against  ER+/PIK3CA-mutated  BC  cells.  The
combination  was  safe  with  reversible  toxicities.  Clinical  activity  was  observed
independently of PIK3CA  mutation status, although clinical benefit was seen in a
higher proportion of patients with PIK3CA-mutated tumours. Phase 2 and 3 trials of
alpelisib and endocrine therapy in patients with ER+ BC are ongoing[22].
PERSPECTIVE
In addition to the previous therapies targeting mTOR, other research groups sought
to  investigate  alternative  strategies  targeting molecules  belonging to  the  mTOR
complex or other effectors of the PI3K-mTOR pathway. An investigatory strategy
consists in the use of sapanisertib (TAK228) for TORC1/2 inhibition by targeting
mTOR kinase. TORC1/2 are complexes of proteins that regulate many vital cellular
processes and proliferation. This drug has been tested in the neoadjuvant setting with
tamoxifen (NCT02988986) or letrozole (NCT02619669) in the treatment of HR+ BC
patients.  AZD5363  is  a  specific  Akt  inhibitor,  which  has  been tested  either  as  a
monotherapy (NCT01226316)  or  as  a  combination with fulvestrant  in HR+ MBC
patients who progressed AIs (NCT01992952). Table 1 summarizes all the clinical trials
testing PI3K-mTOR pathway inhibitors. In our opinion, there is a need for predictors
of the efficacy of such inhibitors: a pooled analysis for overall survival, disease free
survival and PFS meta-analysis using clinical studies investigating the prognostic role
of PI3KCA mutations in BC, proved that mutations of this gene are predictive of a
worse clinical survival outcome for the patients (HR = 1.67, 95%CI: 1.15-2.43; P  =
0.007)[23]. Unfortunately, there was not enough clinical evidence to prove that PI3KCA
mutations  could  be  predictive  for  therapy-efficacy  and  further  clinical  trials
investigating the role of such mutations could be precious for guiding clinicians to
choose those patients who would benefit from PI3K-mTOR inhibition treatment.
In conclusion, the inhibition of the PI3K-mTOR pathway remains one of the major
goals for the treatment of HR+ advanced BC patients. It is known that targeting more
upstream effectors, such as PI3K, which proved to be very promising based on in vitro
evidence,  lead  to  major  side  effects  in  clinical  studies,  limiting  the  clinical
development of this type of drugs. This class of inhibitors, however, seems to be
beneficial for patients harboring PI3KCA mutations, thus producing less toxicity.
Currently,  everolimus  remains  the  best  option  in  the  clinical  setting  in
combinational therapies for HR+ BC patients. Moreover, several studies are directed
to explore the clinical benefits of everolimus in combination with other drugs, as
illustrated in  Table  1.  Of  note,  10%-15% of  patients  are  intrinsically  resistant  to
everolimus treatment[24]. For this reason, dual inhibition of the pathway by targeting
mTORC1/2  proteins  have  been  tested  (Table  1),  and  some  phase  1  studies  are
exploring new PI3K inhibitors, such as gedatolisib (NCT02626507) in neoadjuvant
setting for ER+, HER2- BC patients.  CUDC-907, an histone deacetylase and PI3K
inhibitor (NCT02307240), and AZD8186, a PI3K-β inhibitor (NCT03218826), have been
tested  in  advanced  solid  tumours,  including  BC.  Having  biomarkers  from  the
metastatic setting to predict the responsiveness/resistance to anti-PI3K/mTOR/Akt
drugs are thus an urgent task, and many efforts in this direction are expected. Finally,
with the advancement of immune-therapy, trials testing the combination of immune-
therapy with everolimus are warranted.
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Table 1  Clinical trials inhibiting PI3K-mTOR pathway in HR+, HER2- breast cancer patients
Clinical trial
identifier Phase Year
Administered drug(s)
(target) Primary endpoint
Target/s of the PI3K-
mTOR pathway
NCT00699491 1/2 18.06.2008 Cixutumumab +
temsirolimus
ORR mTOR
Bolero 2;
NCT00863655 [16]
3 18.03.2009 Everolimus +
exemestane or placebo +
exemestane
PFS mTOR
NCT00876395 3 06.04.2009 Everolimus + placebo PFS mTOR
NCT01219699 1 13.10.2010 BYL719 + fulvestrant MTD PI3Kα
NCT01283789 2 26.01.2011 Everolimus + lapatinib ORR mTOR
TAMRAD;
NCT01298713 [14]
2 18.02.2011 Everolimus + tamoxifen CBR mTOR
BELLE-2;
NCT01610284
3 04.06.2012 Fulvestrant ± BKM120
(AIs refractory pts)
PFS PI3K
BELLE-3;
NCT01633060
3 04.06.2012 Fulvestrant ± BKM120
(Pts previously on
mTOR inhibitors)
PFS PI3K
NCT01627067 2 25.06.2012 Everolimus +
exemestane + metformin
PFS mTOR
NCT01674140 3 28.08.2012 Everolimus + standard
adjuvant endocrine
therapy (tamoxifen
citrate, goserelin acetate,
leuprolide acetate,
anastrozole, letrozole, or
exemestane)
Invasive DFS mTOR
Bolero 4; NCT01698918 2 03.10.2012 Everolimus + letrozole PFS mTOR
NCT01776008 2 25.01.2013 everolimus +
exemestane; MK2206 +
anastrozole ± goserelin
acetate
CRR Akt
NCT01783444; Bolero-6 2 05.02.2013 Everolimus or
capecitabine or
everolimus +
exemestane
PFS mTOR
NCT01791478 1 15.02.2013 BYL719 + letrozole DLT PI3Kα
NCT01805271 3 06.03.2013 Everolimus + placebo DFS mTOR
CLEE011X2107;
NCT01872260
1b/2 07.06.2013 Letrozole + ribociclib +
alpesilib
DLT PI3K
INPRES; NCT01948960 4 24.09.2013 Everolimus AUC correlation with
age and/or obesity
mTOR
NCT01992952 1/2 25.11.2013 Fulvestrant ± AZD5363
or placebo
MTD Akt
PEARL; NCT02028364 2 07.01.2014 Everolimus +
exemestane
PFS and response by
PET
mTOR
NCT02035813 2 14.01.2014 Everolimus + eribulin PFS mTOR
NCT02049957 1b/2 30.01.2014 MLN0128 + exemestane
vs MLN0128 +
fulvestrant
Participant with AE and
Clinical Benefit Rate
mTORC1/2
NCT02057133 1b 06.02.2014 LY2835219 +
exemestane +
everolimus vs
exemestane +
everolimus vs
LY2835219 +
trastuzumab vs
LY2835219 + anastrazole
vs LY2835219 +
tamoxifen vs LY2835219
+ letrozole vs LY3023414
+ LY2835219 +
fulvestrant
Safety mTOR
NCT02058381 1b 10.02.2014 BYL719 + BKM120 MTD PI3Kα + PI3K
NCT02077933 1 04.03.2014 Alpelisib + everolimus +
exemestane
DLT and MTD PI3K + mTOR
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NCT02123823 1b 28.04.2014 BI 836845 + everolimus
+ exemestane
PFS, MTD and DLT mTOR
NCT02216786 2 15.08.2014 Everolimus +
fulvestrant vs AZD2014
+ fulvestrant
PFS mTOR + mTORC1/2
NCT02236572 2 10.09.2014 Everolimus + aromatase
inhibitor
Preoperative Endocrine
Prognostic Index
mTOR
NCT02269670 2 21.10.2014 Everolimus + endocrine
therapy (anastrozole,
letrozole, tamoxifen
citrate, fulvestrant or
megestrol acetate)
PFS and ORR mTOR
NCT02285179 1/2 16.11.2014 Taselisib + tamoxifen MTD PI3K
NCT02291913 2 17.11.2014 Everolimus + anti-
estrogen therapy
(exemestane, tamoxifen,
fulvestrant, anastrozole,
letrozole, toremifine )
PFS mTOR
Sandpiper
NCT02340221
3 16.01.2015 Taselisib + fulvestrant vs
placebo + fulvestrant
PFS PI3K
FEVEX; NCT02404051 3 31.03.2015 Everolimus +
exemestane vs
everolimus +
exemestane (at
progression fulvestrant)
PFS mTOR
NCT02404844 2 01.04.2015 BKM120 + tamoxifen PFS PI3K
NCT02379247 04.05.2015 BYL719 + Nab-paclitaxel DLT , ORR for Phase II PI3Kα
SOLAR-1;
NCT02437318
3 07.05.2015 Fulvestrant ± alpelisib
(AIs refractory pts)
PFS PI3K
NCT02506556 2 23.07.2015 BYl719 ORR PI3Kα
NCT02511639 3 30.07.2015 Everolimus + aromatase
inhibitors
PFS mTOR
NCT02520063 1/2 11.08.2015 Letrozole + everolimus
+ TRC105
MTD mTOR
NCT02619669 1 02.12.2015 Sapanisertib + letrozole TAE mTORC1/2
TRINITI-1;
NCT02732119
1/2 08.04.2016 Everolimus + ribociclib
+ exemestane
MTD mTOR
NCT02742051 2 18.04.2016 Everolimus + letrozole
vs neoadjuvant+
fluorouracil, epirubicin
+ cyclophosphamide
(FEC)
ORR mTOR
NCT02871791 2 18.08.2016 Everolimus +
exemestane
DLT mTOR
NCT02988986 2 12.12.2016 Sapanisertib +
tamoxifen
Change in Ki67
expression
mTORC1/2
CLEVER;
NCT03032406
2 26.01.2017 Everolimus ±
hydroxychloroquine
AE mTOR
NCT03056755 2 17.02.2017 Alpelisib + fulvestrant +
letrozole (AIs and
CDK4/6 refractory pts)
DFS PI3K
NCT03128619 1/2 25.04.2017 Copanlisib + letrozole +
palbociclib
MTD PI3K
EVEREXES;
NCT03176238
3 05.06.2017 Everolimus +
exemestane
AE mTOR
NCT03207529 1 02.07.2017 BYL719 + enzalutamide MTD PI3Kα
NCT03377101 2 19.12.2017 Fulvestrant + palbociclib
± copanlisib
DLT PI3K
DLT: Dose limiting toxicity; PFS: Progression free survival; DFS: Disease free survival; MTD: Maximum tolerated dose; AE: Adverse events; CBR: Clinical
benefit rate; ORR: Overall response rate; CRR: Clinical response rate; PI3K-mTOR: Phosphatidylinositol 3-kinase-mammalian target of rapamycin.
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